Health is among the key areas of prime concern among most people. With the advent of the discipline of medicine, health has been improved a great deal. Extensive research has been conducted in the past, and is still an ongoing process, in a bid to curb and eliminate all sorts of health problems. Among the recent breakthroughs is concerned with liposomal formulation.
The formulation is a rightful step in the advancement of drugs. The procedure was discovered to curb the unwanted effects of drugs being exhausted before reaching the target areas. The initial phase of the process involves encapsulating the drug in a layer of digestible and healthy phospholipids. There were several options on the table, but after further research, liposomes were found to be the most favorable carriers.
The simplicity of the liposomes' structural composition is key to its performance. They are made up of an aqueous solution which is engulfed in a strengthened mesh of either natural or synthetic phospholipids. The advantage of this is that it can fuse non-reactively with both hydrophilic and hydrophobic drugs, each attaching to the element it does not react to.
Researchers have found the process of formation of these compounds may be critical to their performance. They are formed when strands of phospholipids are put in water, and a given heat amount is directed to them. The composition of the formed liposomes is tested against that of this drug it is intended to carry, so as to determine compatibility and avoid destructive reactions.
Advances such as these have led to further progress in the medical field. The most famous being development of Doxorubicin, a form of anthracycline. This is a drug that was developed to curb the spread of cancer. It does this in two stages, first, by inserting base stains of DNA and RNA molecules which inhibits replication of cells. The second phase is inhibition of an enzyme known as topoisomerase II, which serves the same purpose of inhibition of cellular growth.
Further research and development on cancer and other terminal ailments have had positive results, and the outcomes lauded by the medical community as well as the general public. Research and testing of liposomes as anti- cancer drug carriers has brought about drugs which are n testing. These include doxorubicin, , lipoplatin, paclitaxel, aroplatin and cisplatin.
The study of liposomes has also led to development of vaccines and various other treatments. Various diseases and medical conditions which previously had no cure can now be vaccinated against. Such developments have established Epaxal, a vaccine against Hepatitis A, and Inflexal V, a vaccine against several types of influenza. A vaccine known as Stimuvax against lighter forms of cancer is in the offing.
Another point of progress thanks to this formulation has been in delivery of dietary supplements. It is still a new area under testing, but has great promise considering the level of success the formulations has garnered from targeted drug delivery. The process of the formulation is hence referred to as a new era of medical advances.
The formulation is a rightful step in the advancement of drugs. The procedure was discovered to curb the unwanted effects of drugs being exhausted before reaching the target areas. The initial phase of the process involves encapsulating the drug in a layer of digestible and healthy phospholipids. There were several options on the table, but after further research, liposomes were found to be the most favorable carriers.
The simplicity of the liposomes' structural composition is key to its performance. They are made up of an aqueous solution which is engulfed in a strengthened mesh of either natural or synthetic phospholipids. The advantage of this is that it can fuse non-reactively with both hydrophilic and hydrophobic drugs, each attaching to the element it does not react to.
Researchers have found the process of formation of these compounds may be critical to their performance. They are formed when strands of phospholipids are put in water, and a given heat amount is directed to them. The composition of the formed liposomes is tested against that of this drug it is intended to carry, so as to determine compatibility and avoid destructive reactions.
Advances such as these have led to further progress in the medical field. The most famous being development of Doxorubicin, a form of anthracycline. This is a drug that was developed to curb the spread of cancer. It does this in two stages, first, by inserting base stains of DNA and RNA molecules which inhibits replication of cells. The second phase is inhibition of an enzyme known as topoisomerase II, which serves the same purpose of inhibition of cellular growth.
Further research and development on cancer and other terminal ailments have had positive results, and the outcomes lauded by the medical community as well as the general public. Research and testing of liposomes as anti- cancer drug carriers has brought about drugs which are n testing. These include doxorubicin, , lipoplatin, paclitaxel, aroplatin and cisplatin.
The study of liposomes has also led to development of vaccines and various other treatments. Various diseases and medical conditions which previously had no cure can now be vaccinated against. Such developments have established Epaxal, a vaccine against Hepatitis A, and Inflexal V, a vaccine against several types of influenza. A vaccine known as Stimuvax against lighter forms of cancer is in the offing.
Another point of progress thanks to this formulation has been in delivery of dietary supplements. It is still a new area under testing, but has great promise considering the level of success the formulations has garnered from targeted drug delivery. The process of the formulation is hence referred to as a new era of medical advances.
